

**PRESS RELEASE**

**Ad hoc announcement pursuant to article 53 LR**

## **LEPU Medical Technology(Beijing) Announces Results of the Year 2022**

Beijing, China, April 25, 2023- LEPU Medical Technology(Beijing) Co.,Ltd.(the “Company”) today announced its performance for the year 2022:

- During the reporting period, the Company realized an operating income of RMB 10609.4421 million , net profit attributable to shareholders of the Company was RMB 2202.8094 million, with a year-on-year increase of 28.12%; net profit attributable to shareholders of the Company after deducting non-recurring profit and loss was RMB 2142.4865 million, with a year-on-year growth of 15.50%; net cash flow from operating activities amounted to RMB 2790.7093 million . The main reason for the decline of the above-mentioned income indicators and net cash flow indicators from operating activities is that the detection reagent products related to COVID-19 contributed a lot to the revenue and net profit in the same period last year.
- At the end of the reporting period, total assets of the Company were RMB 24484.0331 million , with an increase of 18.29% compared with that in the beginning; net assets attributable to shareholders of the Company was RMB 15146.2028 million , with an increase of 32.01% compared with that in the beginning; return on weighted average net assets was 17.60%.

### **Financial Results**

	2022	2021	% Change
Operating revenue(RMB)	10,609,442,080.61	10,659,734,875.07	-0.47%
Net profit attributable to shareholders of the	2,202,809,390.54	1,719,324,578.02	28.12%

Company (RMB)			
Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	2,142,486,458.55	1,854,940,941.11	15.50%
Net cash flows from operating activities (RMB)	2,790,709,307.02	3,061,991,851.71	-8.86%
Basic earnings per share (RMB /share)	1.2223	0.9596	27.38%
Diluted earnings per share (RMB /share)	1.2124	0.9510	27.49%
Return on weighted average net assets	17.60%	16.00%	1.60%

## Full 2022 Annual Report

The full 2022 Annual Report is available on our website at

<https://en.lepumedical.com/investors/>.

## Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: [zqb@lepumedical.com](mailto:zqb@lepumedical.com)

## About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize

a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

## **Disclaimers**

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.